Subscribe By RSS or Email
Theralase Could Light Up Cancer Therapeutics

Theralase Could Light Up Cancer Therapeutics

Cancer patients don’t have many good treatment options. Once the disease is detected, most oncologists will surgically remove as much as possible and then use powerful radiation and chemotherapy to kill as many cells in those areas as possible. The side effects from these treatments can be terrible and patients are at a higher risk […]

Exosomes Shine a Light on Alzheimer’s Disease and CTE

Exosomes Shine a Light on Alzheimer’s Disease and CTE

Concussions are common in recreational and professional sports with an estimated 1.6 million sustained concussion-related injuries per year in the U.S. alone. Since concussions aren’t detectable using X-rays or CT scans, they often go undiagnosed and attempts to prevent them have been difficult. These concussions can lead to far more serious problems like chronic traumatic […]

Discovery Could Lead to Major Breakthrough in Alzheimer’s Disease and Other Brain Disorders

Discovery Could Lead to Major Breakthrough in Alzheimer’s Disease and Other Brain Disorders

Some leading scientists are making strides like never before in research for debilitating and deadly diseases, such as Alzheimer’s Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI).  Currently, people afflicted with these conditions have little hope to avert disease progression and, sadly, death.  There is reason for optimism, though, with hundreds of […]

Recent Articles:

Premier Biomedical Gears Up for Two Important Clinical Trials

Premier Biomedical Inc. (OTC: BIEI), a biopharmaceutical company focused on developing and commercializing innovative therapies targeting cancer, traumatic brain injury, Alzheimer’s disease, MS and other serious conditions, recently announced that the William Beaumont Army Medical

Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic

Fat is driving the bus these days in one narrow, but widening, biotech sector as companies strive for dominance. Among these are Galectin Therapeutics Inc. (NASDAQ: GALT), Intercept Pharmaceuticals (NASDAQ: ICPT), Raptor Pharmaceuticals (NASDAQ: RPTP)

What RXi Pharmaceuticals’ Move to the Russell Microcap Index Means

RXi Pharmaceuticals Corp. (NASDAQ: RXII), a biotechnology company focused on discovering, developing, and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, recently began trading on the Russell Microcap index on June 27,

RXi Pharmaceuticals Appoints Leading Ophthalmology Researcher to Scientific Advisory Board

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing, and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, recently appointed Dr. Peter Campochiaro, a prominent researcher, clinician, and educator

RXi Pharma Centralizes Employee Base in New Facility

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing, and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, recently announced the opening of its new office and laboratory in

Premier Biomedical Secures Key Patent on Feldetrex

Premier Biomedical Inc. (OTC: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune system manipulation therapies for a variety of medical conditions, recently announced that the U.S. Patent Office approved a patent on

Catalysts on the Horizon for Companies Developing NAFLD and NASH Drugs

Those following the developments of Intercept Pharmaceuticals (NASDAQ: ICPT), Galectin Therapeutics (NASDAQ: GALT) and Galmed Pharmaceuticals (NASDAQ: GLMD) are keenly aware of the tendency of fatty liver disease drug developers to move in unity upon

Companies Chasing Gold Nugget of Immuno-Oncology Like Never Before

Probably the most explosive field in biotechnology right now is that of immuno-oncology.  The field is predicated on the concept that the body’s immune system can be augmented or taught to modulate cancer without the

Wall Street Remaining Bullish on Athersys After Interim Data on UC Trial

When it comes to biotechnology stocks, investors can chose to play the blue chip fundamental plays, such as Pfizer (NYSE: PFE) or Novartis (NYSE: NVS), that are typically the subject of investment discussions by high-profile

Premier Biomedical Releases Study Showing Anti-CTLA4′s Potential

Premier Biomedical Inc. (OTC: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune system manipulation therapies for a number of disease and conditions, recently announced the release of a study evaluating strategies for

Theralase’s Cancer Technology Demonstrates Vaccine-Like Properties

Conventional cancer treatment involves surgically removing cancerous tumors and then killing the remaining cells with toxic chemotherapy drugs. Unfortunately, these approaches involve invasive surgeries and the indiscriminant killing of cells that lead to the immune

Theralase CEO Interviewed on Leading Canadian Business News Program

Theralase Technologies Inc. (OTC: TLTFF) (TSX-V: TLT), developer of patented superpulsed laser technology used in eliminating pain and destroying cancer, recently appeared on CBC Television. Theralse President and CEO Roger Dumoulin-White was interviewed by The